776results about "Nanocapsules" patented technology

This invention discloses a composite nanozyme that enhances the clinical efficacy of oxaliplatin, its preparation method, and its application. The composite nanozyme consists of indium ruthenium nanozyme and an iliximab embedding and anchoring layer. The indium ruthenium nanozyme consists of indium ruthenium nanoparticles and a carbon-nitrogen framework, with the indium ruthenium nanoparticles loaded on the surface and within the pores of the carbon-nitrogen framework. The iliximab embedding and anchoring layer consists of a dithiol polyethylene glycol coating layer and iliximab. Preparation method: ZIF-8 is prepared by co-precipitation of zinc salt methanol solution and 2-methylimidazole methanol solution, followed by calcination to obtain the carbon-nitrogen framework. The carbon-nitrogen framework dispersion is then stirred in an oil bath with indium nitrate solution and ruthenium trichloride solution to prepare a nanozyme precursor, followed by calcination to obtain indium ruthenium nanozyme. The indium ruthenium nanozyme is dispersed in a dithiol polyethylene glycol solution, and iliximab solution is added dropwise. The resulting solid product is then dried. This invention can solve problems such as strong drug tolerance, insufficient intracellular accumulation, and severe tumor immunosuppression in oxaliplatin treatment.

The application provides a lipoic acid doped lipid nanoparticle and a preparation method and application thereof, and belongs to the technical field of biological medicines.The lipoic acid doped lipid nanoparticle provided by the application is composed of nucleic acid drugs and a lipid composition, and the lipid composition is composed of ionizable lipids, sterols, PEGylated lipids, auxiliary lipids and lipoic acid.The application has the beneficial effect that the nucleic acid drug delivery effect of the traditional four-component lipid nanoparticle can be enhanced by introducing lipoic acid, and high-efficiency nucleic acid drug transfection can be achieved without causing obvious cytotoxicity, and the biological safety is high.

The application discloses an oral nano-vaccine and a preparation method and application thereof, and relates to the technical field of immunology, and specifically discloses an oral nano-vaccine which comprises a nano-particle wrapped by a biomimetic bacterial membrane vesicle and an outer layer; the nano-particle comprises an antigen and a biodegradable polymer material; the biomimetic bacterial membrane vesicle comprises an ionizable flagellar lipoprotein, an immune adjuvant, a phospholipid, a sterol lipid and a polyethylene glycol lipid; and the outer layer is a pH-responsive polymer. The oral nano-vaccine provided by the application combines the immune activation advantages of natural bacterial membrane vesicles and the precise regulation characteristics of synthetic materials, significantly improves the transmembrane penetration capacity of the antigen in the intestinal epithelium and the overall activation effect of the mucosal immune system. The oral nano-vaccine provided by the application can protect the antigen and the immune adjuvant from degradation and realize precise release in the intestinal microenvironment; and the oral nano-vaccine significantly improves the bioavailability and safety of an oral tumor vaccine, and lays a key technical foundation for clinical transformation and large-scale production of the oral tumor vaccine.

The present invention relates to RNA-containing vaccine compositions for inducing an immune response to Porphyromonas gulae in a subject, and uses thereof.

Providing nanoparticles for use in the treatment of eye diseases. [Solution] The present invention relates to nanoparticles for use in a method of effectively preventing or treating one or more inflammatory components, immune response components, angiogenic components and neuropathic components of retinal disease or optic neuropathy in patients, comprising: a core containing a drug having one or more of the following: anti-inflammatory activity, immunosuppressive activity, anti-angiogenic activity, neuroprotective activity, gene therapy activity and gene expression regulatory activity; an amphiphilic shell surrounding the core, the amphiphilic shell comprising at least one phospholipid and optionally at least one surfactant; and a targeted ligand covalently bound to the amphiphilic shell, which binds to receptors expressed on the surface of retinal pigment epithelial (RPE) cells and / or endothelial cells and / or optic nerve cells.

Provided herein are compositions and methods of reducing adduct formation.

This invention relates to a self-adjuvanted biomimetic lipid nanoparticle, its microfluidic assembly method, and its anti-tumor applications. The self-adjuvanted biomimetic lipid nanoparticle has a structure in which an activated dendritic cell membrane (ADCM) is coated on the surface of a lipid nanoparticle (LNP) loaded with mRNA. The advancements of this invention compared to traditional LNPs are: the self-adjuvanted biomimetic lipid nanoparticle (ADCM-LNP) exhibits a faster cellular uptake rate and higher transfection efficiency, thereby inducing a strong Th1-type immune response and a potent CTL-mediated tumor-killing effect. In vivo biodistribution studies have shown that this system exhibits significant spleen-targeting (splenic tropism) and demonstrates excellent therapeutic efficacy in a HER2-positive breast cancer model.

The present disclosure relates to lymphatic endothelial cell (LEC)-specific lipid nanoparticle comprising a sterol, an ionizable lipid, a PEGylated lipid, and a phospholipid. Also disclosed herein are compositions comprising the LEC-specific lipid nanoparticle and a therapeutic agent. The present disclosure further relates to methods of delivering an agent to a lymphatic system in a subject, comprising administering to the subject an effective amount of the composition of the LEC-specific lipid nanoparticle and therapeutic agent.

Disclosed herein are nanoparticles comprising one or more Human papillomavirus (HPV) antigen and nucleic acid molecules encoding the same. Also disclosed herein is a method of treating a HPV infection or treating or preventing a disease or disorder associated therewith in a subject in need thereof, by administering the nanoparticles, or encoding nucleic acid molecules, to the subject.

Provided herein are compositions, systems, and methods comprising effector proteins and uses thereof. These effector proteins may be characterized as engineered CRISPR-associated (Cas) proteins. Various compositions, systems, and methods of the present disclosure may leverage the activities of these effector proteins for the editing, detecting and / or engineering of nucleic acids.

The application relates to the field of triple-negative breast cancer treatment and relates to synthesis of an acid-responsive amphiphilic liposome and application of the acid-responsive amphiphilic liposome in tumor treatment. A chemotherapeutic drug, a phospholipid, cholesterol and a polyethylene glycolized lipid are dissolved in an organic solvent chloroform, vacuum rotary evaporation is carried out under certain temperature and rotation rate, a water phase is added for hydration, a polypeptide nanogold cluster solution is added for ultrasonic treatment, then crushing, molecular sieve screening, dialysis and ultrafiltration are carried out to obtain a pH-sensitive liposome; in the preparation process, the phospholipid spontaneously forms a kind of biological membrane-like phospholipid bilayer membrane vesicle in water, and the chemotherapeutic drug and the nanogold cluster are wrapped in the vesicle. The pH-sensitive liposome can target the triple-negative breast cancer tumor site through pH response, can improve the solubility of the chemotherapeutic drug, can realize high-efficiency treatment effect of the drug at a low dose, can obviously reduce the toxic side effect of the chemotherapeutic drug, and can realize effective treatment of the triple-negative breast cancer.

The application discloses a liver-targeted gene editing system based on endogenous promoter hijacking and application, and belongs to the field of biological medicine. The system is composed of an LNP-wrapped modified Cas nuclease mRNA (first component) and a promoter-free viral vector carrying a therapeutic transgene donor (second component). The system uses LNP to realize the transient burst expression of Cas nuclease in the liver, mediates the generation of double-strand breaks at the site of endogenous high-expression genes, induces the site-specific integration of therapeutic transgenes without exogenous promoters, and hijacks the expression driven by endogenous promoters by using the splice acceptor (SA) mechanism. The application solves the risk of carcinogenesis caused by random integration of exogenous strong promoters and the immunotoxicity of long-term expression of nucleases through a "double safety lock" design. Experimental results prove that the system has high editing efficiency, long-term stability and no off-target, and can be used for various liver-derived metabolic diseases such as hemophilia, hypercholesterolemia and the like.

The present invention relates to a lipid nanoparticle and a method for preparing same, wherein melittin, a peptide capable of directly penetrating cell membranes and facilitating mucus layer penetration, is conjugated with a biocompatible lipid to form a melittin-lipid conjugate and is used in combination with an ionizable lipid, a helper lipid, cholesterol, and a lipid-PEG to prepare the lipid nanoparticle, whereby the lipid nanoparticle exhibits high stability and low toxicity while effectively delivering influenza A virus mRNA via intranasal administration to induce a prophylactic vaccine effect.

The application belongs to the field of medical materials, and particularly relates to a metal core enhanced double-barrier piezoelectric nano system and a preparation method and application thereof. The preparation method comprises the following steps: first, a core-shell structure of'metal@mesoporous titanium dioxide@mesoporous barium titanate' is prepared through a step-by-step reaction, and then the target nanoparticles are obtained through lipid wrapping. The system innovatively constructs a double-barrier structure, can self-trigger active oxygen under a physiological pressure of 4 mmHg, realizes endogenous pressure self-driven treatment of malignant ascites, has the advantages of low pressure, high catalytic efficiency, long-term structural stability and good biocompatibility, solves the problems that existing treatment methods are highly invasive and depend on exogenous stimulation, and provides a new safe and efficient technical scheme for the treatment of malignant ascites.

The application provides a cationic lipid compound and a preparation method and use thereof. The cationic lipid compound has a structure shown in formula I. The cationic lipid compound provided by the application has a simple chemical structure and is easy to synthesize, and can be used for preparing a drug carrier, in particular a nucleic acid drug carrier. The drug-loaded lipid nanoparticle containing the cationic lipid compound has a small particle size, a uniform particle size distribution, and good loading and delivery effects on nucleic acid drugs.

The present application relates to the field of pharmaceutical preparation and nanomedicine, and particularly relates to a kind of nano-drug composition, its combined drug delivery system and application.The nano-drug composition comprises alpha 1-AR blocker and amphiphilic nano-carrier;The alpha 1-AR blocker is loaded in the hydrophobic core formed by amphiphilic nano-carrier;The alpha 1-AR blocker is selected from one or more of prazosin, terazosin, doxazosin;The average particle size of the nano-drug composition is 220-260 nm, the polydispersity index is less than 0.3, and the encapsulation efficiency is greater than 50%.The nano-drug composition of the present application has dual functions of anti-tumor proliferation and immune microenvironment remodeling, improves the dispersion stability of the drug in physiological medium, effectively reduces the in vivo clearance rate, prolongs the circulation time, and realizes the efficient in vivo delivery of the drug.The preparation process of the nano-preparation is stable and can be produced on a large scale.

The application discloses application of PTN in preparation of products for treating cognitive impairment caused by severe infection. The inhibitor of PTN provided by the application can inhibit chronic neuroinflammation, thereby preventing and inhibiting formation and development of late cognitive impairment caused by severe infection, and meanwhile, inhibition of expression or function of PTN can effectively block damage of infiltrating macrophages to microglia cells, thereby providing a new direction for treatment of related diseases.

A composition for treating cancer is provided, comprising a DDB2 inhibitor and a chemotherapeutic agent, wherein the DDB2 inhibitor comprises three RNA fragments derived from lincRNA-p21. Furthermore, the DDB2 inhibitor enhances the chemosensitivity of cancer to chemotherapeutic agents for the treatment of cancers that are unresponsive to chemotherapy.

The present application relates to the technical field of disease detection, and more particularly to a method for diagnosing and treating early atherosclerotic plaques based on multifunctional nanomaterial CeOx-P@PM, which comprises the following steps: S1: assembling CeOx with a MMP2 specific probe to form a CeOx-P compound; and S2: coating the CeOx-P compound with a biomimetic platelet membrane as a carrier to assemble CeOx-P@PM nanoparticles. The method for diagnosing and treating early atherosclerotic plaques based on multifunctional nanomaterial CeOx-P@PM has the excellent characteristics of efficient ROS removal, high bioavailability, lesion targeting, and dual-mode precise imaging, and will provide great help for the diagnosis and treatment of early atherosclerotic plaques in clinical practice.

This invention relates to a polypeptide for gene delivery, a polypeptide / nucleic acid molecular complex prepared therefrom, and its applications. The polypeptide of this application has the structure shown in Formula I, wherein Formula I contains an immune cell targeting group represented by Y. The polypeptide developed in this application, as a gene delivery carrier, has a highly efficient nucleic acid loading capacity. Furthermore, it exhibits high delivery efficiency to immune cells both in vitro and in vivo, thus showing broad application prospects in the immune cell-targeted delivery of genes.

This invention relates to the field of biotechnology, specifically to a method for screening highly efficient and low-toxicity mRNA delivery vectors based on an ionizable lipid library. The method includes: S1. Providing a lipid library containing at least 100 structurally diverse ionizable lipids; S2. Using an automated microfluidic platform, mixing each ionizable lipid in the lipid library with helper lipids, cholesterol, PEG-lipids, and reporter gene mRNA, respectively, to prepare a lipid nanoparticle (LNP) library in parallel; S3. Performing high-throughput in vitro screening on the LNP library; S4. Selecting the ionizable lipids corresponding to the LNPs with the top 10% efficacy scores and cell viability values ​​greater than 80% as Hit (initial positive candidates); S5. Performing rapid in vivo validation of the Hit; S6. Determining the final selected lipids based on the criteria of in vivo liver expression intensity > 200% of the positive control and ALT < 100 U / L. This method for screening highly efficient and low-toxicity mRNA delivery vectors based on an ionizable lipid library can more effectively screen for non-toxic mRNA delivery vectors.

Described herein are compositions, kits, and methods for potent delivery to a cell of a subject. The cell can be of a particular cell type, such as a basal cell. In some cases, the cell can be a lung cell of a particular cell type. Also described herein are pharmaceutical compositions comprising a therapeutic or prophylactic agent assembled to a lipid composition. The lipid composition can comprise an ionizable cationic lipid, and a selective organ targeting lipid. The lipid composition can further comprise a phospholipid. Further described herein are high-potency intravenous dosage forms of a therapeutic or prophylactic agent formulated with a lipid composition.

The application relates to preparation and application of a giant Eimeria nanosubunit vaccine. The nanosubunit vaccine PLGA-rEmLPL is prepared by coating E. maxima Treg-induced molecule EmLPL recombinant protein (rEmLPL) with PLGA nanoparticles. The immunoprotective effects of the subunit vaccine rEmLPL and the nanosubunit vaccine PLGA-rEmLPL are evaluated through animal immunoprotection tests, and the results show that both the vaccines can produce good immunoprotective effects on E. maxima infection. After the recombinant protein subunit vaccine rEmLPL is coated with the PLGA nanoparticles, the immunoprotective effect of the nanosubunit vaccine PLGA-rEmLPL on animals is improved compared with that of the subunit vaccine rEmLPL.

The present invention relates to nanoparticles comprising sirolimus and albumin, a pharmaceutical composition comprising the same for subcutaneous administration, and a method for preparing the same. In the case of using the preparation method of the present invention, nanoparticles comprising sirolimus and albumin having excellent stability of particle size distribution can be prepared, the prepared nanoparticles can be prepared as a pharmaceutical composition suitable for subcutaneous injection, and the increase in administration dose and the convenience of administration can be improved.

Provided herein is a method for preparing the nanoparticle comprising: (i) combining an aqueous phase comprising the nucleic acid with an organic solvent-lipid mixture comprising lipids, wherein the lipids comprise an ionizable lipid and at least one helper lipid and optionally a hydrophilic-polymer lipid conjugate; wherein the aqueous phase comprises a buffer having a concentration of at least 100 mM and has an aqueous phase pH that is lower than a pKa of the ionizable lipid such that the ionizable lipid is substantially charged; wherein the lipid nanoparticle is formed during or subsequent to the combining; and (ii) exchanging a solution external to the lipid nanoparticle with a higher pH solution, thereby producing the nucleic-acid lipid nanoparticle, wherein the nucleic-acid lipid nanoparticle comprises one or more bleb compartments.

The application discloses a brush-like structure barrier adaptive nucleic acid drug delivery system and a preparation method and application thereof, and belongs to the technical field of polymer chemistry and biological medicine, wherein the delivery system is prepared through click reaction or cycloaddition reaction of a poly-bis-sulfur main chain, a modified nucleic acid drug and a modified polyampholyte; the poly-bis-sulfur main chain is a random copolymer, comprising a bis-sulfur structural unit A and an acrylate structural unit B, the bis-sulfur structural unit A is formed through ring-opening polymerization of thioctic acid and is modified with a click reaction functional group or a cycloaddition reaction functional group; the modified nucleic acid drug is modified with a click reaction functional group or a cycloaddition reaction functional group on at least one base; the modified polyampholyte is modified with a click reaction functional group or a cycloaddition reaction functional group; the delivery system can endow the nucleic acid drug with the ability to break through the skin and mucus barriers, and can be used for the treatment or prevention of various diseases according to the type and quantity of the carried nucleic acid drug.

The invention relates to mRNA comprising lipid nanoparticles and their medical uses. The lipid nanoparticles of the present invention comprise a cationic lipid according to formula (I), (II) or (III) and / or a PEG lipid according to formula (IV), as well as an mRNA compound comprising an mRNA sequence encoding an antigenic peptide or protein. The invention further relates to the use of said lipid nanoparticles as vaccines or medicaments, in particular with respect to influenza or rabies vaccination.

Provided in the present invention are an ionizable liposome compound and a drug delivery system containing the ionizable liposome. Specifically, provided in the present invention are an ionizable liposome having a structure of formula (I), or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, and a prodrug thereof. Lipid nanoparticles constructed by using the ionizable liposome can achieve safe and efficient delivery of nucleic acid drugs, small molecule drugs, peptide drugs, and protein drugs.

The application provides a drug delivery system for targeted treatment of inflammatory diseases and a preparation method and application thereof, and belongs to the technical field of biological drugs. The drug delivery system for targeted treatment of inflammatory diseases is M2 type macrophages phagocytizing drug-loaded nanoparticles, wherein the drug-loaded nanoparticles comprise a biodegradable high molecular material for coating drugs. The drug delivery system prepared by the application realizes lung targeted delivery through the natural inflammatory chemotaxis characteristics of M2 type macrophages, and in combination with the drug slow-release effect of the drug-loaded nanoparticles, the drug targeting and availability are significantly improved, so that the drug efficacy is improved, the biological safety is good, and a new effective means is provided for the clinical treatment of various inflammatory diseases including carbapenem-resistant Klebsiella pneumoniae (CRKP) pneumonia.